Publications

Mueller MJ*, Aicher HD*, Dornbierer DA*, Marten L, Suay D, Meling D, Elsner C, Wicki IA, Müller J, Poetzsch SN, Caflisch L, Hempe A, Steinhart CP, Puchkov M, Kost J, Landolt HP, Seifritz E, Quednow BB, Scheidegger M. Pharmacokinetics and Pharmacodynamics of an Innovative Psychedelic N,N-Dimethyltryptamine/Harmine Formulation in Healthy Participants: A Randomized Controlled Trial. Int J Neuropsychopharmacol. 2025 Jan 8:pyaf001. https://doi.org/10.1093/ijnp/pyaf001

Meling D, Egger K, Aicher HD, Jareño Redondo J, Mueller J, Dornbierer J, Temperli E, Vasella EA, Caflisch L, Pfeiffer DJ, Schlomberg JT, Smallridge JW, Dornbierer DA, Scheidegger M. Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat. J Psychopharmacol. 2024 Oct;38(10):897-910. https://doi.org/10.1177/02698811241282637

Egger K, Aicher HD, Cumming P, Scheidegger M. Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors. Cell Mol Life Sci. 2024 Sep 10;81(1):395. https://doi.org/10.1007/s00018-024-05353-6

Singer B, Meling D, Hirsch-Hoffmann M, Michels L, Kometer M, Smigielski L, Dornbierer D, Seifritz E, Vollenweider FX, Scheidegger M. Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation. Sci Rep. 2024 Mar 26;14(1):7211. https://doi.org/10.1038/s41598-024-55726-x

Aicher HD*, Mueller MJ*, Dornbierer DA, Suay D, Elsner C, Wicki I, Meling D, Caflisch L, Hempe A, Steinhart C, Mueller J, Von Rotz R, Kleim B, Scheidegger M. Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects. Front Psychiatry. 2024 Jan 8;14:1302559. https://doi.org/10.3389/fpsyt.2023.1302559

Dornbierer DA, Marten L, Mueller J, Aicher HD, Mueller MJ, Boxler M, Kometer M, Kosanic D, von Rotz R, Puchkov M, Kraemer T, Landolt HP, Seifritz E, Scheidegger M. Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine. Front Pharmacol. 2023 Nov 27;14:1246892. https://doi.org/10.3389/fphar.2023.1246892

Meling D, Scheidegger M. Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective. Front Psychol. 2023 Apr 3;14:1100058. https://doi.org/10.3389/fpsyg.2023.1100058

Scheidegger M. Psychedelic Medicines: A Paradigm Shift from Pharmacological Substitution Towards Transformation-Based Psychiatry. In: Labate BC, Cavnar C (eds): Ayahuasca Healing and Science. Cham: Springer. 2021; 43-61. https://doi.org/10.1007/978-3-030-55688-4_3

Smigielski L*, Scheidegger M*, Kometer M, Vollenweider FX. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage. 2019 Aug 1;196:207-215. https://doi.org/10.1016/j.neuroimage.2019.04.009

Jungaberle H, Thal S, Zeuch A, Rougemont-Bücking A, von Heyden M, Aicher H, Scheidegger M. Positive psychology in the investigation of psychedelics and entactogens: A critical review. Neuropharmacology. 2018 Nov;142:179-199. https://doi.org/10.1016/j.neuropharm.2018.06.034

https://www.webofscience.com/wos/author/record/S-2358-2017